MiPLA
MiPLA is a lesser-known psychedelic of the lysergamide class and a structural isomer of LSD.citation needed First discovered by Albert Hofmann during the original structure-activity research for LSD, it was later studied in greater detail by David E. Nichols at Purdue University. MiPLA is reported to produce effects similar to LSD but with a shorter duration, subtler visuals, a less introspective headspace, and a generally less anxiety-provoking profile. It is approximately two- to threefold less potent than LSD.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
MiPLA produces a classic lysergamide psychedelic experience that closely resembles LSD in overall character, though it is generally reported as milder and shorter-lasting at comparable doses, with human potency estimated at roughly one third to one half that of LSD. The experience is often described as gentle and manageable, following a familiar arc of gradual onset, a plateau of moderate psychedelic alteration, and a comparatively smooth return to baseline.
Physical
The body load is generally mild, with light stimulation and few pronounced physical effects reported.
Cognitive
The headspace is commonly described as relatively light and lucid, with a mild euphoric tone and less cognitive force or intensity than LSD.
Visual
Visual effects are present but typically subtler than those of LSD, scaling with dose in the usual lysergamide fashion.
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
MiPLA principally acts as an agonist at the serotonin 5-HT2A receptor, which is considered its primary mechanism for producing psychedelic effects. One source characterizes it specifically as a partial agonist at this site. It also interacts with dopamine D1 and D2 receptors, and more broadly shares a similar monoamine receptor binding profile with LSD across serotonin, dopamine, and norepinephrine systems.citation needed MiPLA has approximately 33 to 50% of the potency of LSD and fully substitutes for LSD in rodent drug discrimination assays.12
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of MiPLA and the metabolism of MiPLA is unknown.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Serotonergic psychedelics (due to shared activity at the 5-HT2A receptor)
Harm Potential
Addiction & Dependence
Psychological
Extremely LowLike other serotonergic psychedelics, MiPLA is believed to have a low potential for abuse and psychological dependence, owing to its structural and pharmacological similarities with LSD.citation needed These claims are preliminary and based on anecdotal rather than clinical evidence.
Physical
Extremely LowMiPLA is believed to have a low potential for dependence based on its structural and pharmacological similarities with LSD and other serotonergic psychedelics. No physical dependence has been documented.citation needed
Psychosis Risk
MiPLA may trigger psychiatric difficulties in people with pre-existing psychiatric conditions. People with their own history of mental illness, or a family history of it, are generally advised to avoid this substance. Delusions and other adverse psychological reactions are more likely at higher doses.
Seizure Risk
The possibility of seizures is extrapolated from rarely reported cases with LSD. Seizures are thought to mainly be a risk in those who are genetically predisposed, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment.citation needed
History & Culture
MiPLA was originally synthesized by Albert Hofmann at Sandoz Laboratories as part of the foundational structure-activity relationship research into LSD. Eli Lilly and Company subsequently filed a patent for the compound in 1956, with formal publication following in 1961.…
Legality
By Country
AustriaIllegal (analog/blanket ban)
GermanyNpSG controlled
SwitzerlandRestricted
United StatesNot scheduledReferences
Source Pages
Citations
- Xuemei Huang, Danuta Marona-Lewicka, Robert C. Pfaff, & David E. Nichols. (March 1994). Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacology Biochemistry and Behavior, 47(3), 667–673. https://doi.org/10.1016/0091-3057(94)90172-41
- Adam L. Halberstadt, Landon M. Klein, Muhammad Chatha, Laura B. Valenzuela, Alexander Stratford, Jason Wallach, David E. Nichols, & Simon D. Brandt. (February 2019). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology (Berl), 236(2), 799–808. https://doi.org/10.1007/s00213-018-5055-91
- Neue-Psychoaktive-Substanzen-Verordnung (NPSV), consolidated Austrian text, version 27 August 2026. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007642/NPSV%2c%20Fassung%20vom%2027.08.2026.pdf1
- Neue-Psychoaktive-Substanzen-Verordnung, Anlage II no. 11 (BGBl. II Nr. 106/2024). ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf1
- Neue-Psychoaktive-Substanzen-Gesetz (NPSG), consolidated Austrian text, version 27 August 2026. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007605/NPSG%2c%20Fassung%20vom%2027.08.2026.pdf1
- Anlage NpSG. Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection] (n.d.). https://www.gesetze-im-internet.de/npsg/anlage.html1
- § 4 NpSG. Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection] (n.d.). https://www.gesetze-im-internet.de/npsg/__4.html1
- Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), status 13 March 2026. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20260313/de/pdf-a/fedlex-data-admin-ch-eli-cc-2011-363-20260313-de-pdf-a.pdf1
- DEA Diversion Control Division, Controlled Substance Schedules (August 2026). deadiversion.usdoj.gov (n.d.). https://www.deadiversion.usdoj.gov/schedules/schedules.html1
- 21 U.S.C. §813, Treatment of controlled substance analogues (preliminary current text). uscode.house.gov (n.d.). https://uscode.house.gov/view.xhtml?req=%28title%3A21+section%3A813+edition%3Aprelim%291
Further Reading
Nichols, D.E. (2001) - LSD and its lysergamide cousins- Nichols, D.E. (2001) - LSD and its lysergamide cousins
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
31 July 2026
14 July 2026
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the MiPLA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.